Evidence map›Paper›PMID 42668551›Full record

ArticleIDCases2026

A case of prolonged cefiderocol therapy during continuous hemodiafiltration in a patient with an implanted left ventricular assist device.

Hiroshi Kimura, Takaaki Yano, Yukiro Kurokawa, Shinobu Murakami, Hitoshi Miyamoto, Noriaki Hidaka, Hisamichi Tauchi, Mamoru Tanaka

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroshi KimuraDivision of Pharmacy, Ehime University Hospital, Toon, Ehime, Japan.
Takaaki YanoDivision of Pharmacy, Ehime University Hospital, Toon, Ehime, Japan.
Yukiro KurokawaDivision of Pharmacy, Ehime University Hospital, Toon, Ehime, Japan.
Shinobu MurakamiDivision of Infection Control and Prevention, Ehime University Hospital, Toon, Ehime, Japan.
Hitoshi MiyamotoDivision of Infection Control and Prevention, Ehime University Hospital, Toon, Ehime, Japan.
Noriaki HidakaDivision of Pharmacy, Ehime University Hospital, Toon, Ehime, Japan.
Hisamichi TauchiDivision of Infection Control and Prevention, Ehime University Hospital, Toon, Ehime, Japan.
Mamoru TanakaDivision of Pharmacy, Ehime University Hospital, Toon, Ehime, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefiderocol (CFDC) is a siderophore cephalosporin with activity against multidrug-resistant Gram-negative pathogens, and it is considered a treatment option for refractory Gram-negative infections. Because CFDC is primarily eliminated by the kidneys, dose individualization is required in patients with renal impairment and in those receiving renal replacement therapy. During continuous hemodiafiltration (CHDF), drug clearance is influenced not only by residual renal function but also by dialysis and filtration flow rates and membrane characteristics; thus, careful determination of dose and dosing interval is necessary. However, real-world evidence on CFDC dosing during CHDF, particularly for prolonged courses, remains limited. We report a case of refractory

Indexed as

BacteremiaCefiderocolContinuous hemodiafiltrationLeft ventricular assist devicePseudomonas aeruginosa

Identifiers

PMID42668551
PMCPMC13524692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.